CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer

摘要

BackgroundThe identification of high-risk stage II colon cancers is key to the selection of patients who require adjuvant treatment after surgery. Microarray-based multigene-expression signatures derived from stem cells and progenitor cells hold promise, but they are difficult to use in clinical practice.